Antiangiogenic potential of 10-hydroxycamptothecin

被引:32
作者
Xiao, D [1 ]
Tan, WF [1 ]
Li, MH [1 ]
Ding, J [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai Inst Biol Sci,State Key Lab Drug Res, Shanghai 200031, Peoples R China
关键词
10-hydroxycamptothecin; angiogenesis inhibitor; human microvascular endothelial cells; CAM assay; apoptosis;
D O I
10.1016/S0024-3205(01)01236-X
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
To investigate the antiangiogenic potential of 10-hydroxycamptothecin (HCPT), the proliferation of human microvascular endothelial cells (HMEC) and seven human tumor cell lines were detected by SRB assay, and the endothelial cell migration and tube formation were assessed using two in vitro model systems. Also, inhibition of angiogenesis was determined with a modification of the chick embryo chorioallantoic membrane (CAM) assay in vivo. Morphological assessment of apoptosis was performed by fluorescence microscope. HCPT 0.313-5 mu mol.L-1 treatment resulted in a dose-dependent inhibition of proliferation, migration and tube formation in HMEC cells, and HCPT 6.25-25 nmol.egg(-1) inhibited angiogenesis in CAM assay. HCPT 1.25-5 mu mo1.L-1 elicited typical morphological changes of apoptosis including condensed chromatin, nuclear fragmentation, and reduction in volume in HMEC cells. HCPT significantly inhibited angiogenesis both in vitro and in vivo at relatively low concentrations, and this effect was related with induction of apoptosis in HMEC cells. These results taken collectively suggest that HCPT may be a potent antiangiogenetic and cytotoxic drug and further investigation is warranted. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1619 / 1628
页数:10
相关论文
共 18 条
[1]   CAMP-MEDIATED SIGNALS AS DETERMINANTS FOR APOPTOSIS IN PRIMARY GRANULOSA-CELLS [J].
AHARONI, D ;
DANTES, A ;
OREN, M ;
AMSTERDAM, A .
EXPERIMENTAL CELL RESEARCH, 1995, 218 (01) :271-282
[2]   Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A2 [J].
Ashton, AW ;
Yokota, R ;
John, G ;
Zhao, SM ;
Suadicani, SO ;
Spray, DC ;
Ware, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) :35562-35570
[3]   Antiangiogenic potential of camptothecin and topotecan [J].
Clements, MK ;
Jones, CB ;
Cumming, M ;
Daoud, SS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (05) :411-416
[4]  
DOUGLAS H, 2000, J CLIN INVEST, V105, P1045
[5]   Tumour vasculature as a target for anticancer therapy [J].
Eatock, MM ;
Schätzlein, A ;
Kaye, SB .
CANCER TREATMENT REVIEWS, 2000, 26 (03) :191-204
[6]   Angiogenesis: New targets for the development of anticancer chemotherapies [J].
Gourley, M ;
Williamson, JS .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) :417-439
[7]   Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo [J].
Isaji, M ;
Miyata, H ;
Ajisawa, Y ;
Takehana, Y ;
Yoshimura, N .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (06) :1061-1066
[8]   'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples [J].
Kerbel, RS ;
Viloria-Petit, A ;
Klement, G ;
Rak, J .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) :1248-1257
[9]  
LING YH, 1993, ANTICANCER RES, V13, P1613
[10]  
Liu WM, 1998, INT J ONCOL, V12, P793